Preferred Label : Anti-CD33/BET Degrader ADC ABBV-787;
NCIt synonyms : Anti-CD33 ADC ABBV-787; Antibody-drug Conjugate ABBV-787;
NCIt definition : An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against
the tumor-associated antigen (TAA) CD33 conjugated to a bromodomain and extra-terminal
domain (BET) degrader payload, with potential antineoplastic activity. Upon administration
of anti-CD33/BET degrader ADC ABBV-787, the monoclonal antibody portion of ABBV-787
specifically targets and binds to the cell surface antigen CD33 expressed on myeloid
leukemia cells. Upon internalization, the BET degrader payload is released and leads,
through an as of yet not fully elucidated mechanism, to the degradation of BET proteins
by the ubiquitin-proteasome system. This dysregulates gene expression and specifically
leads to the downregulation of the expression of certain growth-promoting genes, which
may inhibit the proliferation of BET-overexpressing and CD33-expressing tumor cells.
CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia
cells. BET family of proteins, comprised of bromodomain-containing proteins 2 (BRD2),
3 (BRD3), and 4 (BRD4) as well as bromodomain testis-specific protein (BRDT), are
transcriptional regulators that are overexpressed in certain tumor cells and play
important roles during cellular development and growth.;
Molecule name : ABBV-787; ABBV 787;
Origin ID : C213074;
concept_is_in_subset
- has_target
